Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Am J Vet Res. 2016 Sep;77(9):1005–1016. doi: 10.2460/ajvr.77.9.1005

Figure 2.

Figure 2

A) Pharmacokinetics of HA-Pt treated dogs with oral squamous cell carcinomas. B) Pharmacokinetics of HA-Pt treated dogs with nasal cancers or sarcomas. C) A three-compartmental model of HA-Pt pharmacokinetics. D) Pharmacokinetic parameters calculated by fitting plasma concentration vs time data to a three-compartmental model. Each dog was modeled individually. *Patients 07, 08, 10, 11, and 16 were excluded due to the incomplete elimination phase.